Seres Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $736 | $358 | $438 | $351 |
Gross Profit | 736 | -423 | 14,243 | -13,001 |
EBITDA | -21,273 | -19,132 | -13,200 | 9,263 |
EBIT | -19,913 | -15,335 | 8,204 | |
Net Income | 4,581 | -19,913 | -15,335 | 8,204 |
Net Change In Cash | 736 | 358 | 438 | 351 |
Free Cash Flow | -22,394 | -16,360 | -14,739 | 2,198 |
Cash | 15,594 | 29,834 | 45,766 | 47,638 |
Basic Shares | 9,644 | 9,582 | 8,869 | 8,771 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $789 | $0 | $126,325 | $7,128 |
Gross Profit | -3,344 | -3,532 | -19,341 | 6,124 |
EBITDA | 9,829 | -120,303 | -181,419 | -170,932 |
EBIT | 5,696 | -125,771 | -187,662 | -177,561 |
Net Income | 5,696 | -146,571 | -113,724 | -250,157 |
Net Change In Cash | 789 | 0 | 126,325 | 7,128 |
Cost of Revenue | -16,786 | |||
Free Cash Flow | 865 | -148,989 | -125,329 | -238,637 |
Cash | 45,766 | 30,793 | 127,965 | 163,030 |
Basic Shares | 8,869 | 7,770 | 6,400 | 5,403 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$1.50 |
2026-03-31 | -$2.08 |
2025-12-31 | -$1.76 |
2025-09-30 | $0.94 |